Track 14: Metaplastic Breast Cancer:-
Metaplastic Breast Cancer pathology outlines:-
An uncommon and aggressive kind of breast cancer is called metaplastic breast cancer. Typically, it manifests as a rapidly expanding tumour or lump in the breast.
The tumour frequently resembles an invasive ductal carcinoma during imaging tests, a kind of breast cancer that originated in a milk duct and has since migrated to surrounding tissue outside the duct. However, metaplastic breast cancer tumours are typically bigger when they are discovered.
Metaplastic breast cancer cells resemble a variety of cancer kinds when seen under a microscope. This formerly led medical professionals to think that it initially begins as two distinct tumours that eventually merge. Emerging evidence, however, points to metaplastic breast cancer as a single malignancy that may have started in very young cells with the capacity to differentiate into many types of mature cells.
Prognosis for Metaplastic Breast Cancer:-
Metaplastic breast cancer grows more quickly than other types of breast cancer and is more likely to metastasis, or spread to other regions of the body. Additionally, following a successful initial treatment, it is more likely to return.
About 55% of individuals with metaplastic breast cancer survive five years after diagnosis. The current survival rate may be greater since those who were diagnosed within the previous few years and may have gotten newer, more potent therapies are not included in this statistic.
Treatment for Metaplastic Breast Cancer:-
Less than 1% of all breast cancer diagnoses are for metaplastic breast cancer. There haven’t been many clinical trials focused on the condition because it is so uncommon. According to current recommendations, it should be treated similarly to other breast tumours of the same stage and characteristics.
Triple-negative receptor status is present in the majority of metaplastic breast tumours. The oestrogen receptor, progesterone receptor, and HER2 gene/protein are not overexpressed in these breast tumours. Triple-negative tumours are difficult to treat using medications that target these characteristics of cancer cells. There is a need for further treatment plans.
Treatment normally begins with chemotherapy to decrease the tumour if the patient’s cancer is discovered before it has progressed over the breast and nearby lymph nodes. Immunotherapy may also be used in this situation. Following this course of treatment, surgery and sometimes radiation therapy are used.
Chemotherapy or other cancer medications, either by alone or in combination, are typically used to treat cancer that has progressed past the breast and the lymph nodes nearby. Radiation may be used to lessen the discomfort brought on by a tumour mass.
Track 14: Metaplastic Breast Cancer:-
